Horizon Therapeutics (HZNP) Tops Q2 EPS by 19c

Horizon Therapeutics (NASDAQ: HZNP) reported Q2 EPS of $1.20, $0.19 better than the analyst estimate of $1.01. Revenue for the quarter came in at $945 million versus the consensus estimate of $897.62 million.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49